These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effect of interleukin-1, GM-CSF, erythropoietin, and lithium on the toxicity associated with 3'-azido-3'-deoxythymidine (AZT) in vitro on hematopoietic progenitors (CFU-GM, CFU-MEG, and BFU-E) using murine retrovirus-infected hematopoietic cells. Gallicchio VS, Hughes NK, Hulette BC, Noblitt L. J Leukoc Biol; 1991 Dec; 50(6):580-6. PubMed ID: 1940611 [Abstract] [Full Text] [Related]
5. Suppression of murine hematopoiesis in vivo after chronic administration of zidovudine: evidence that zidovudine-induced anemia is the result of decreased bone marrow-derived, erythropoietin-responsive progenitor cells. Gallicchio VS, Hughes NK. Proc Soc Exp Biol Med; 1992 Apr; 199(4):459-65. PubMed ID: 1549625 [Abstract] [Full Text] [Related]
6. Effect of combination interleukin-1 and erythropoietin in ameliorating the hematopoietic toxicity associated with the use of zidovudine administered to normal mice. Gallicchio VS, Hughes NK, Tse KF, Gaines H. Life Sci; 1994 Apr; 54(20):PL351-61. PubMed ID: 8190019 [Abstract] [Full Text] [Related]
7. Additive effect of erythropoietin and heme on murine hematopoietic recovery after azidothymidine treatment. Harrison J, Kappas A, Levere RD, Lutton JD, Chertkov JL, Jiang S, Abraham NG. Blood; 1993 Dec 15; 82(12):3574-9. PubMed ID: 8260696 [Abstract] [Full Text] [Related]
8. Effect of combination interleukin-3 (IL-3) and granulocyte-macrophage colony stimulating factor (GM-CSF) on hematopoiesis administered to retrovirus-infected immunodeficient mice receiving dose-escalation zidovudine (AZT). Gallicchio VS, Hughes NK, Tse KF, Ling J, Gaines H, Bowen TE, Uluitu M. Int J Immunopharmacol; 1995 Nov 15; 17(11):865-78. PubMed ID: 8788116 [Abstract] [Full Text] [Related]
9. Influence of interleukin-3 (IL-3) on the hematopoietic toxicity associated with combination anti-viral drugs (zidovudine and DDI) in vitro using retrovirus-infected bone marrow cells. Gallicchio VS, Hughes NK. Int J Immunopharmacol; 1994 Apr 15; 16(4):359-66. PubMed ID: 8045675 [Abstract] [Full Text] [Related]
10. Inhibitory effects of zidovudine in erythroid progenitor cells. Reversal with a combination of erythropoietin and interleukin-3. Gogu SR, Beckman BS, Wilson RB, Agrawal KC. Biochem Pharmacol; 1995 Jul 31; 50(3):413-9. PubMed ID: 7646543 [Abstract] [Full Text] [Related]
11. Increased hematopoietic toxicity following administration of interferon-a with combination dideoxynucleoside therapy (zidovudine plus ddI) administered in normal mice. Gallicchio VS, Scott KW, Hughes NK, Tse KF, Gaines H, Kirk PR, Birch NJ. Life Sci; 1995 Jul 31; 56(3):PL71-81. PubMed ID: 7823768 [Abstract] [Full Text] [Related]
12. Differential effect of erythropoietin and GM-CSF on megakaryocytopoiesis from primitive bone marrow cells in serum-free conditions. Cardier JE, Erickson-Miller CL, Murphy MJ. Stem Cells; 1997 Jul 31; 15(4):286-90. PubMed ID: 9253112 [Abstract] [Full Text] [Related]
13. Influence of interleukin-3 on zidovudine (AZT)-induced in vitro toxicity to human hematopoietic progenitors. Gallicchio VS, Hughes NK. Int J Cell Cloning; 1992 Mar 31; 10(2):99-104. PubMed ID: 1545155 [Abstract] [Full Text] [Related]
14. Protection of 3'-azido-3'-deoxythymidine induced toxicity to murine hematopoietic progenitors (CFU-GM, BFU-E and CFU-MEG) with interleukin-1. Gallicchio VS, Doukas MA, Hulette BC, Hughes NK, Gass C. Proc Soc Exp Biol Med; 1989 Nov 31; 192(2):201-4. PubMed ID: 2813453 [Abstract] [Full Text] [Related]
15. Comparison of dideoxynucleoside drugs (DDI and zidovudine) and induction of hematopoietic toxicity using normal human bone marrow cells in vitro. Gallicchio VS, Hughes NK, Tse KF. Int J Immunopharmacol; 1993 Feb 31; 15(2):263-8. PubMed ID: 8468123 [Abstract] [Full Text] [Related]
16. In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P. Blood; 1989 Feb 15; 73(3):678-83. PubMed ID: 2783864 [Abstract] [Full Text] [Related]
17. Influence in vitro of IL-3/Epo fusion proteins compared with the combination of IL-3 plus Epo in enhancing the proliferation of single isolated erythroid and multipotential progenitor cells from human umbilical cord blood and adult bone marrow. Lu L, Xiao M, Li ZH, Jolliffe LK, Jones S, Broxmeyer HE, Weich N. Exp Hematol; 1995 Sep 15; 23(10):1130-4. PubMed ID: 7656932 [Abstract] [Full Text] [Related]
19. Optimal erythroid cell production during erythropoietin treatment of mice occurs by exploiting the splenic microenvironment. Nijhof W, Goris H, Dontje B, Dresz J, Loeffler M. Exp Hematol; 1993 Apr 15; 21(4):496-501. PubMed ID: 8462658 [Abstract] [Full Text] [Related]
20. Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15. Pierelli L, Scambia G, Bonanno G, Coscarella A, De Santis R, Mele A, Battaglia A, Fattorossi A, Romeo V, Menichella G, Mancuso S, Leone G. Exp Hematol; 1999 Mar 15; 27(3):416-24. PubMed ID: 10089903 [Abstract] [Full Text] [Related] Page: [Next] [New Search]